Effect of MPTP on Serotonergic Neuronal Systems and Mitochondrial Complex I Activity in the Living Brain: A PET Study

Masakatsu Kanazawa1, Hiroyuki Ohba1, Shingo Nishiyama1

  • 1Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan.

Insights

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes widespread mitochondrial complex I (MC-I) damage and reduces dopamine and serotonin transporter levels in a Parkinson

Area of Science:

  • Neuroscience
  • Radiochemistry
  • Pharmacology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder primarily affecting dopaminergic neurons.
  • 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin used to model PD in non-human primates.
  • The neurotoxic effects of MPTP on serotonergic systems and mitochondrial complex I (MC-I) are not fully understood.

Purpose of the Study:

  • To compare the effects of MPTP on serotonergic neuronal systems and MC-I activity versus dopaminergic systems.
  • To investigate the distribution and extent of MPTP-induced neurotoxicity in the brain using Positron Emission Tomography (PET).

Main Methods:

  • A Parkinson disease monkey model was established through repeated MPTP administration.
  • PET imaging was performed using radioligands targeting serotonin transporter (11C-DASB), serotonin 1A receptor (18F-MPPF), dopamine transporter (11C-PE2I), dopamine synthesis (11C-6MemTyr), dopamine D2 receptor (11C-raclopride), and MC-I (18F-BCPP-EF).
  • Quantitative PET analyses were conducted using cerebellum as the input function for serotonin and dopamine parameters, and Logan plot analysis for MC-I.

Main Results:

  • MPTP induced diffuse reductions in MC-I activity across the brain, excluding the cerebellum.
  • Significant reductions in presynaptic dopamine transporter and dopamine synthesis were observed in the striatum and substantia nigra.
  • MPTP reduced serotonin transporter binding in both striatal and extrastriatal regions, correlating with MC-I reduction in the cortex; serotonin 1A receptor binding remained unaffected.

Conclusions:

  • Chronic MPTP treatment causes significant neurotoxicity extending beyond the nigrostriatal pathway, affecting both dopaminergic and serotonergic systems.
  • MPTP-induced MC-I damage in extrastriatal regions supports its non-exclusive neurotoxicity to the nigrostriatal pathway.
  • Multiparametric PET imaging reveals widespread neurochemical alterations in an MPTP-induced Parkinson's disease monkey model.